Hacking Your Own Genes: A Recipe for Disaster

Hacking Your Own Genes: A Recipe for Disaster

Employees of ODIN, a consumer genetic design and engineering company, working out of their Bay Area garage start-up lab in 2016.

(Courtesy Josiah Zayner)


Keep Reading Keep Reading
Marcy Darnovsky
Marcy Darnovsky, PhD, is Executive Director at the Center for Genetics and Society, a Berkeley, California-based public affairs organization working to encourage responsible uses and effective societal governance of human genetic and assisted reproductive technologies. She speaks and writes widely on human biotechnologies, focusing on their social justice, equity, human rights, and public interest implications. Her articles have appeared in The New York Times, Nature, The Guardian, Los Angeles Times, Wall Street Journal, New Scientist, and many others. Beyond Bioethics: Towards a New Biopolitics, an anthology co-edited with Osagie K. Obasogie, is forthcoming in March 2018 from the University of California Press. Her Ph.D. is from the History of Consciousness program at the University of California, Santa Cruz. (Photo credit Barry Zuckerman)
Hidden figures: Five black women that changed science forever

Dr. May Edward Chinn, Kizzmekia Corbett, PhD., and Alice Ball, among others, have been behind some of the most important scientific work of the last century.


Keep Reading Keep Reading
Sarah Watts

Sarah Watts is a health and science writer based in Chicago.

natural killer cell
NIAID, CC BY 2.0 <https://creativecommons.org/licenses/by/2.0>, via Wikimedia Commons

On today’s episode of Making Sense of Science, I’m honored to be joined by Dr. Paul Song, a physician, oncologist, progressive activist and biotech chief medical officer. Through his company, NKGen Biotech, Dr. Song is leveraging the power of patients’ own immune systems by supercharging the body’s natural killer cells to make new treatments for Alzheimer’s and cancer.

Whereas other treatments for Alzheimer’s focus directly on reducing the build-up of proteins in the brain such as amyloid and tau in patients will mild cognitive impairment, NKGen is seeking to help patients that much of the rest of the medical community has written off as hopeless cases, those with late stage Alzheimer’s. And in small studies, NKGen has shown remarkable results, even improvement in the symptoms of people with these very progressed forms of Alzheimer’s, above and beyond slowing down the disease.

Keep Reading Keep Reading
Matt Fuchs
Matt Fuchs is the host of the Making Sense of Science podcast and served previously as the editor-in-chief of Leaps.org. He writes as a contributor to the Washington Post, and his articles have also appeared in the New York Times, WIRED, Nautilus Magazine, Fortune Magazine and TIME Magazine. Follow him @fuchswriter.